InsidersTradesSigma
Total declarations
Company
▲ Purchases (7 ops.)
▼ Sales (15 ops.)
Insider track record
CEODisclosed buys
7
Disclosed sells
15
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Niklason Laura E, Chairman & CEO. Insider active across 1 company, notably Humacyte, Inc.. In total, 26 disclosures have been logged. Split: 7 buys · 15 sells. Total volume traded: €47.9m. Activity tracked since 14 December 2021. The latest transaction was disclosed on 19 November 2024 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations26 total
1,797 shares@ US$4.440.0% of flowCommon StockSEC:0001818382-24-000214:0
Ideal exit: 16 Aug 2025 (T+270)
811,172 shares@ US$4.447.1% of flowCommon StockSEC:0001818382-24-000208:0
157,704 shares@ US$5.421.6% of flowCommon StockSEC:0001818382-24-000184:0
1,222 shares@ US$6.5450.0% of flowCommon StockSEC:0001818382-24-000177:0
Ideal exit: 26 May 2025 (T+270)
252,676 shares@ US$6.713.2% of flowCommon StockSEC:0001818382-24-000166:0
282,000 shares@ US$7.09223.9% of flowCommon StockSEC:0001818382-24-000101:0
716,573 shares@ US$7.7810.7% of flowCommon StockSEC:0001818382-24-000084:0
2,362 shares@ US$6.350.0% of flowCommon StockSEC:0001818382-24-000087:0
Ideal exit: 1 Mar 2025 (T+270)
2,050 shares@ US$7.370.0% of flowCommon StockSEC:0001818382-24-000076:0
Ideal exit: 28 Feb 2025 (T+270)
114,420 shares@ US$1.190.3% of flowCommon StockSEC:0001818382-23-000153:0
2,000,000 shares@ US$2.7814.8% of flowCommon StockSEC:0001818382-23-000130:0
570,174 shares@ US$3.684.0% of flowCommon StockSEC:0001818382-23-000121:0
500,000 shares@ US$3.11753.0% of flowCommon StockSEC:0001818382-23-000083:0
4,875,000 shares@ US$2.6024.4% of flowCommon StockSEC:0001818382-23-000049:0
2,625,000 shares@ US$2.7514.0% of flowCommon StockSEC:0001104659-23-065546:0
100,000 shares@ US$1.190.2% of flowCommon StockSEC:0001818382-23-000003:0
239,538 shares@ US$2.531.2% of flowCommon StockSEC:0001818382-22-000221:0
10,000 shares@ US$2.540.0% of flowCommon StockSEC:0001818382-22-000223:0
Ideal exit: 11 Sept 2023 (T+270)
330,000 shares@ US$2.841.8% of flowCommon StockSEC:0001818382-22-000211:0
1,522,500 shares@ US$4.0012.7% of flowCommon StockSEC:0001818382-22-000161:0
2,000 shares@ US$4.140.0% of flowCommon StockSEC:0001818382-22-000167:0
Ideal exit: 12 Jun 2023 (T+270)
10,000 shares@ US$4.839.9% of flowCommon StockSEC:0001818382-22-000050:0
Ideal exit: 17 Feb 2023 (T+270)
23,694 shares@ US$9.7980.4% of flowCommon StockSEC:0001104659-21-150678
23,694 shares@ US$9.79845.0% of flowCommon StockSEC:0001104659-21-150678:0
1,148,240 sharesCommon StockSEC:0001104659-21-110547:0
25 of 26 declarations
About Niklason Laura E
Laura E. Niklason is the President, CEO and Director at Humacyte, Inc. She leads the company with a focus on innovation in the field of cell therapies. Her leadership is essential for the development and implementation of new medical solutions.
